Quantcast

Latest Nuvo Research Inc. Stories

2014-06-11 16:27:04

MISSISSAUGA, ON, June 11, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company with a diverse portfolio of topical and immunology products today announced that at its 2014 Annual and Special Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated April 30, 2014 were elected as directors of the Company. The detailed results of the votes by proxy are as follows: Director Nominees...

2014-05-29 08:29:40

MISSISSAUGA, ON, May 29, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products today announced that a third party has received U.S. Food and Drug Administration (FDA) approval to market and sell a topical diclofenac sodium 1.5% solution in the United States. The product is a generic version of Nuvo's PENNSAID (diclofenac sodium topical solution) 1.5% w/w (PENNSAID 1.5%). Mallinckrodt Inc. (NYSE:MNK)...

2014-04-23 08:31:25

MISSISSAUGA, ON, April 23, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced a collaboration involving Ferndale Laboratories, Inc. (Ferndale) and a leading Contract Research Organization (CRO) with significant dermatology experience to develop two topical dermatology products based on Nuvo's patented Multiplexed Molecular Penetration Enhancer (MMPE(TM)) technology. "This...

2014-04-01 08:28:19

MISSISSAUGA, ON, April 1, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), (the "Company"), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, is pleased to announce the closing of a non-brokered private placement (the "Private Placement"), pursuant to which an aggregate of 1,390,000 units of the Company were issued at a price of $2.25 per unit, raising gross proceeds of approximately $3,127,500. Each Unit consists of one common share...

2014-02-20 16:26:45

MISSISSAUGA, ON, Feb. 20, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced its financial and operational results for the fourth quarter and year ended December 31, 2013. "In 2013 and early 2014, we significantly advanced our three FDA approved commercial products that will contribute to Nuvo revenues. Pennsaid 2% was approved and launched in the U.S., Pliaglis was...

2014-02-10 08:26:43

MISSISSAUGA, ON, Feb. 10, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products today announced the U.S. commercial launch of PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) by its U.S. commercial licensee Mallinckrodt (NYSE:MNK). PENNSAID 2% is the first twice per day topical non-steroidal anti-inflammatory drug (NSAID) approved for use in the United States for the...

2014-01-17 08:22:56

- Mallinckrodt to Launch PENNSAID 2% in the U.S. in Q1 2014 - MISSISSAUGA, ON, Jan. 17, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of products in the areas of topical pain and immunology today announced that the U.S. Food and Drug Administration (FDA) has approved Mallinckrodt's New Drug Application for PENNSAID(®) (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%). PENNSAID 2% is a follow-on product to...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related